<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04842201</url>
  </required_header>
  <id_info>
    <org_study_id>CM326HV001</org_study_id>
    <nct_id>NCT04842201</nct_id>
  </id_info>
  <brief_title>Single Ascending Dose Study of CM326 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Randomized, Placebo-Controlled, Double-blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CM326 in Adult Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Keymed Biosciences Co.Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Keymed Biosciences Co.Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single ascending dose study to evaluate the safety, tolerability, pharmacokinetics,&#xD;
      pharmacodynamics and immunogenicity of CM326 in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 16, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Actual">September 28, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of CM326 by assessing the number and severity of adverse events, including changes in vital signs, physical examination, laboratory safety tests, and ECGs</measure>
    <time_frame>Day 1 through Day 85</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of CM326</measure>
    <time_frame>Day 1 through Day 85</time_frame>
    <description>Serum concentrations of CM326 over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of CM326</measure>
    <time_frame>Day 1 through Day 85</time_frame>
    <description>Serum total Immunoglobulin E (IgE) and Thymus and activation regulated chemokine (TARC) over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Day 1 through Day 85</time_frame>
    <description>anti-drug antibody (ADA)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>CM326</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CM326</intervention_name>
    <description>subcutaneous injection</description>
    <arm_group_label>CM326</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>subcutaneous injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult male participant,18 to 65 years of age, inclusive.&#xD;
&#xD;
          -  Body Mass Index (BMI) 18 to 26 kg/m2, inclusive.&#xD;
&#xD;
          -  History, physical examination, laboratory tests and test related items of inspection&#xD;
             were normal or abnormal without clinically insignificant.&#xD;
&#xD;
          -  Males must abstain from sex or use highly effective methods of birth control.&#xD;
&#xD;
          -  Having given written informed consent prior to undertaking any study-related&#xD;
             procedure.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Positive for HIV, or Hepatitis B, or C.&#xD;
&#xD;
          -  Positive result on urine drug screen.&#xD;
&#xD;
          -  Clinical laboratory abnormalities of clinical significance, or other clinical findings&#xD;
             suggest clinically significant following diseases (including, but not limited to the&#xD;
             gastrointestinal tract, kidney, liver, nerve, blood, endocrine, cancer, lung, immune,&#xD;
             mental or cardiovascular disease).&#xD;
&#xD;
          -  With any condition that inappropriate for entry into this study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Hou</last_name>
    <role>Principal Investigator</role>
    <affiliation>PKUcare luzhong hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PKUCare Luzhong Hospital</name>
      <address>
        <city>Zibo</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 8, 2021</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

